secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001641172-25-010348
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi reports Q1 net loss $5.0M; CEO transition to Eric Poma; FDA clears CLD-201 IND
--------------------------------------------------------------------------------

- CEO transition: Eric Poma appointed CEO; 30+ yrs biopharma; raised >$250M at Molecular Templates.
- FDA cleared IND for CLD-201 (allogeneic stem cell therapy) for solid tumors; CIRM non-dilutive funding.
- Selected IL-15 superagonist as first payload for Redtail platform; IND filing expected H2 2026.
- Q1 net loss $5.0M ($0.18/share) vs $7.2M ($2.03/share) in Q1 2024; R&D $2.4M, G&A $2.6M.
- Cash $10.6M at March 31, 2025, up from $9.6M at Dec 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000164117225010348/0001641172-25-010348-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000164117225010348/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-010348

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer